Positive Phase III data for Invokana in T2D-Janssen

Janssen has announced results from a post-hoc analysis which showed that at 52 weeks, Invokana (canagliflozin) provided reductions in both HbA1c and body weight in more patients with Type 2 Diabetes as an add-on to metformin, when compared with sitagliptin or glimepiride. This analysis used data from two separate Phase III studies of canagliflozin 100mg and 300mg versus either sitagliptin 100mg or glimepiride. Results showed a greater proportion of patients had reductions in both HbA1c and body weight with canagliflozin 100mg and 300mg compared with sitagliptin 100mg (67.7%, 74.7%, and 50.6%, respectively), or glimepiride (72.4%, 78.5%, and 26.8%, respectively). Canagliflozin 300mg was associated with the greatest reductions in HbA1c and body weight compared to sitagliptin 100mg and glimepiride.

In the first study comparing canagliflozin to sitagliptin, mean HbA1c changes from baseline were -0.73%, -0.88%, and -0.73%, and mean body weight changes from baseline were -3.8%, -4.2%, and -1.3% with canagliflozin 100mg and 300mg and sitagliptin 100mg, respectively. In the second study comparing canagliflozin to glimepiride, mean HbA1c changes from baseline were -0.82%, -0.93%, and -0.81%, and mean body weight changes from baseline were -4.2%, -4.7%, and 1.0% with canagliflozin 100mg and 300mg and glimepiride, respectively. A greater proportion of patients had reductions in both HbA1c and body weight with canagliflozin 100mg and 300mg compared with sitagliptin 100mg (67.7%, 74.7%, and 50.6%, respectively) or glimepiride (72.4%, 78.5%, and 26.8%, respectively). Data were presented at the European Association for the Study of Diabetes Annual Meeting.